Systematic review reports on repeat CAR-T therapy outcomes in patients with relapsed B-cell malignancies, indicating suboptimal responses but potential benefits.
Key Points
To evaluate the outcomes of repeat CAR-T therapy in patients with B-cell malignancies who did not respond adequately to initial treatment.
Conducted a systematic review and meta-analysis following PRISMA guidelines.
Performed a comprehensive search using PubMed, Cochrane, Embase, and ClinicalTrials.gov.
Selected five studies inclusive of different patient populations and analyzed outcomes using statistical methods.
Included data from 133 patients, indicating overall response rate (ORR) of 55%.
Observed a complete response rate of 42% and a partial response rate of 13%.
Median progression-free survival after CART2 was reported as 6.2 months and median overall survival as 11.2 months.